

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

KMS-11

RRID:CVCL_2989

Type: Cell Line

Proper Citation

RRID:CVCL_2989

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2989

Proper Citation: RRID:CVCL_2989

Description: Cell line KMS-11 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:2519219](#), [PMID:2768132](#), [PMID:8943038](#), [PMID:9787181](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:15215163](#), [PMID:15491288](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Produces IgG kappa., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMS-11

Synonyms: KMS11, kms11, kms 11, Kawasaki Medical School-11

Cross References: BTO:BTO_0003932, EFO:EFO_0005694, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-1088, BioGRID_ORCS_Cell_line:911, BioSample:SAMN03473171,

BioSample:SAMN10987857, cancercelllines:CVCL_2989, CCRID:1101HUM-PUMC000682, Cell_Model_Passport:SIDM00608, CGH-DB:21-1, CGH-DB:9133-4, ChEMBL-Cells:ChEMBL4295454, ChEMBL-Targets:ChEMBL4296454, Cosmic:720765, Cosmic:759900, Cosmic:759906, Cosmic:760389, Cosmic:760402, Cosmic:760645, Cosmic:850216, Cosmic:1740213, Cosmic:2081391, Cosmic:2302410, Cosmic:2367280, Cosmic:2391798, Cosmic:2809763, Cosmic-CLP:1659817, DepMap:ACH-000714, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002414, EGA:EGAS00001002554, ENCODE:ENCBS682HMC, ENCODE:ENCBS987CHP, GDSC:1659817, GEO:GSM143337, GEO:GSM290294, GEO:GSM562810, GEO:GSM887220, GEO:GSM888294, GEO:GSM1666387, GEO:GSM1692593, GEO:GSM1692594, GEO:GSM1692595, JCRB:JCRB1179, JCRB:NIHS0482, LiGeA:CCLE_189, PharmacoDB:KMS11_762_2019, PRIDE:PXD030304, Progenetix:CVCL_2989, PubChem_Cell_line:CVCL_2989, Wikidata:Q54900162

ID: CVCL_2989

Record Creation Time: 20220427T220705+0000

Record Last Update: 20260815T234428+0000

Ratings and Alerts

No rating or validation information has been found for KMS-11.

Warning: Discontinued: JCRB; NIHS0482

Characteristics: Produces IgG kappa., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 209 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Adhikary U, et al. (2026) Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling. Cancer research, 86(11), 2810.

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Tang K, et al. (2026) Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. Advanced science (Weinheim,

Baden-Wurttemberg, Germany), 13(21), e18975.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. *Journal of molecular medicine (Berlin, Germany)*, 104(1), 45.

Yin Z, et al. (2025) Cinobufagin overcomes bortezomib resistance in multiple myeloma strains by targeting SEC62/TRPM4-mediated NECISO. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 147, 157171.

Oikonomidi I, et al. (2025) Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. *PLoS biology*, 23(4), e3003096.

Fang T, et al. (2025) A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28. *Biomarker research*, 13(1), 57.

Heredia-Guerrero SC, et al. (2024) Functional Investigation of IGF1R Mutations in Multiple Myeloma. *Cancers*, 16(11).

Peng P, et al. (2024) Pro-survival signaling regulates lipophagy essential for multiple myeloma resistance to stress-induced death. *Cell reports*, 43(7), 114445.

Ye T, et al. (2024) Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. *Cell reports*, 43(5), 114211.

Okada M, et al. (2023) Detection of mutant antigen-specific T cell receptors against multiple myeloma for T^{CR} cell engineering. *Molecular therapy. Methods & clinical development*, 29, 541.

Ailawadhi S, et al. (2023) AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. *Cancers*, 15(2).

Okayama M, et al. (2023) GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c-MET tyrosine kinase. *Cancer medicine*, 12(8), 9749.

Chow S, et al. (2023) Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing. *Life science alliance*, 6(1).

Harada T, et al. (2023) Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. *Blood advances*, 7(6), 1019.

Tsukamoto T, et al. (2023) Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. *Journal of human genetics*, 68(7), 507.

Rashan LJ, et al. (2023) Molecular Modes of Action of an Aqueous Nerium oleander Extract in Cancer Cells In Vitro and In Vivo. *Molecules (Basel, Switzerland)*, 28(4).

Kurata K, et al. (2023) BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(9), 1807.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.